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Abstract
Background: One of the most thoroughly studied systems in relation to its prognostic relevance
in patients with breast cancer, is the plasminogen activation system that comprises of, among
others, the urokinase Plasminogen Activator (uPA) and its main inhibitor, the Plasminogen
Activator Inhibitor-1 (PAI-1). In this study, we investigated the prognostic value of uPA and PAI-1 at
the mRNA level in lymph node- and hormone receptor-positive breast cancer.
Methods:  The study included a retrospective series of 87 patients with hormone-receptor
positive and axillary lymph node-positive breast cancer. All patients received radiotherapy, adjuvant
anthracycline-based chemotherapy and five years of tamoxifen treatment. The median patient age
was 54 and the median follow-up time was 79 months. Distant relapse occurred in 30 patients and
22 patients died from breast cancer during follow-up. We investigated the prognostic value of uPA
and PAI-1 at the mRNA level as measured by real-time quantitative RT-PCR.
Results: uPA and PAI-1 gene expression was not found to be correlated with any of the established
clinical and pathological factors. Metastasis-free Survival (MFS) and Breast Cancer specific Survival
(BCS) were significantly shorter in patients expressing high levels of PAI-1 mRNA (p < 0.0001; p <
0.0001; respectively). In Cox multivariate analysis, the level of PAI-1 mRNA appeared to be the
strongest prognostic factor for MFS (Hazard Ratio (HR) = 10.12; p = 0.0002) and for BCS (HR =
13.17; p = 0.0003). Furthermore, uPA gene expression was not significantly associated neither with
MFS (p = 0.41) nor with BCS (p = 0.19). In a Cox-multivariate regression analysis, uPA expression
did not demonstrate significant independent prognostic value.
Conclusion: These findings indicate that high PAI-1 mRNA expression represents a strong and
independent unfavorable prognostic factor for the development of metastases and for breast
cancer specific survival in a population of hormone receptor- and lymph node-positive breast
cancer patients.
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Background
The serine protease urokinase-type Plasminogen Activator
(uPA) and its inhibitor, the Plasminogen Activator Inhib-
itor type 1 (PAI-1), are key players in the proteolytic cas-
cade involved in physiological and pathophysiological
degradation and remodeling of the extracellular matrix. In
the past two decades, study of the uPA and PAI-1 system
in human breast cancer has yielded valuable insights. Sev-
eral international research groups have demonstrated that
the protein content of uPA and PAI-1 in the tumor corre-
lates with disease aggressiveness and has a strong prog-
nostic impact on disease-free survival and overall survival
in patients with primary breast cancer [1-6]. A pooled
analysis of 8,377 breast cancer patients from 18 different
data sets further confirmed the strong and independent
prognostic value of uPA/PAI-1 [7]. The observation that
the prognostic strength of uPA and PAI-1 was substan-
tially influenced by the administration of adjuvant chem-
otherapy has led the German investigators to hypothesize
that these markers might also have important predictive
value [8,9]. Several recent analyses indicated that breast
cancer patients with high uPA/PAI-1 protein levels derived
a significantly greater benefit from adjuvant chemother-
apy than patients with low uPA/PAI-1 contents [10,11]. In
the multi-center prospective Chemo N0 trial, administra-
tion of cyclophosphamide/methotrexate/5-fluorouracil-
based chemotherapy led to a substantial reduction in the
risk of disease recurrence in patients with high uPA/PAI-1
[8]. In contrast, the correlation between uPA/PAI-1 status
and the benefits from adjuvant endocrine therapy appears
to be more contradictory [10-13]. Nevertheless, in meta-
static breast cancer, retrospective studies showed that ele-
vated uPA or PAI-1 present in the primary tumor are
associated with a poor response to later palliative endo-
crine therapy [14] suggesting that high levels of uPA and/
or PAI-1 do reflect an aggressive phenotype that may be
overcome by early systemic therapy in the adjuvant setting
but not by palliative therapy at a later stage of the disease.
All these studies referred to gene expression at the protein
level, as measured by quantitative enzyme immunoassays
in cytosols prepared for hormone receptor assays with
quality control programs developed by the EORTC Recep-
tor and Biomarker Study Group [15]. However, despite
attaining the of highest level of evidence for clinical appli-
cation, uPA and PAI-1 are not widely used in clinical prac-
tice. This is in part due to the growing abandonment of
classical biochemical methods for assessing hormone
receptors. In the 1990s, an increased number of pathology
laboratories started to measure hormone receptors by
immunohistochemistry on paraffin sections and bio-
chemical methods were less used, mainly because they are
poorly adapted to small tumors, the numbers of which are
growing due to widespread breast cancer screening cam-
paigns. The measurement of uPA and PAI-1 expression at
the mRNA level by real-time quantitative Nucleic Acid
Sequence-Based Amplification (NASBA) or RT-PCR,
which both need very small amounts of RNA and thus
allows the analysis of early-stage tumors, may constitute
an alternative to the study of the parameters at the protein
level.
In spite of adjuvant chemotherapy and endocrine therapy,
about 20% of all lymph node-positive, hormone receptor-
positive patients suffer from tumor relapse [16]. The risk
of disease recurrence should ideally be identified prior to
therapeutic decision making, so that the treatment
options can be adapted to the patient's prognosis. Unfor-
tunately, beyond HER2 expression, until now, no biolog-
ical factor allows us to predict in which patients classical
chemo and endocrine therapy will be sufficient. Thus, in
order to gain insight in this domain, we selected a retro-
spective series of 87 lymph node-, hormone receptor-pos-
itive breast cancer patients who received chemotherapy
and endocrine treatment in an adjuvant setting to investi-
gate the prognostic significance of uPA and PAI-1 mRNA
expression.
Methods
Patient characteristics
The 87 patients included in the study were diagnosed at
the Centre Léon Bérard (Lyon, France) with hormone
receptor-positive, axillary lymph node-positive breast can-
cer between 1992 and 1999. The study was approved by
the institutional review board of the hospital. Fresh frozen
tissue from the tumor samples was obtained after breast
surgery prior to therapy. All patients were free of metas-
tases at the time of diagnosis. The histological subtype was
defined according to WHO standards and the histological
grade was assessed according to the score of Scarf, Bloom
and Richardson (SBR). Steroid receptor status was deter-
mined by immunohistochemistry, and tumors were
judged to be receptor-positive when >10% of the cells
were stained. The median patient age was 54 (ranging
from 29–74) and the median follow-up time was 79
months (ranging from 1–153 months). All patients
received radiotherapy, adjuvant polychemotherapy and
five years of Tamoxifen treatment. The standard chemo-
therapy regimen consisted of either four cycles of doxoru-
bicin or epirubicin given in combination with
cyclophosphamide [4× AC/EC], or six cycles of 5-flourou-
racil, doxorubicin/epirubicin and cyclophosphamide [6×
FAC/FEC]. Distant relapse occurred in 30 patients, and 22
patients died from breast cancer during follow-up. The
main patient's characteristics are summarized in Table 1.
Real-time quantitative RT-PCR analysis
Single strand cDNA was prepared from 200 ng of total
RNA using the ThermoScript™ reverse transcriptase system
(Invitrogen, California, USA) at 55°C for 60 min followedBMC Cancer 2006, 6:216 http://www.biomedcentral.com/1471-2407/6/216
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by RNAse H reaction at 37°C for 20 min in order to
remove RNA template. The final RT product was diluted at
1:10 in diethyl pyrocarbonate-treated water and stored at
-20°C. Real-time PCR reactions were performed using a
LightCycler™ instrument and the Fast-Start™ DNA Master
SYBR Green I real-time PCR kit (Roche Diagnostics, Man-
nheim, Germany). Thermocycling was performed accord-
ing to the manufacturer's recommendations in a final
volume of 20 µl containing 2 mM MgCl2, 0.3 µM of each
of the required primers and 10 µl of the appropriate cDNA
dilution. PCR was carried out with an initial denaturation
step of 10 min at 95°C, followed by 40 cycles consisting
of 10s at 95°C for denaturation, 10s at 68°C (with a pro-
gressive temperature decrease of 0.5°C per cycle, from
68°C to 58°C) for step annealing and 16 s at 72°C for the
final extension step. The quantification of uPA and PAI-1
mRNA levels was carried out with regard to the cyclophilin
B (PPIB) housekeeping gene expression, according to the
LightCycler™ Relative Quantification Software instruc-
tions (Roche Diagnostics, Mannheim, Germany). Four
logarithmic dilutions of a linearized plasmid containing
the target fragment were prepared in quadruplicate to gen-
erate standard curves by plotting the crossing point (Cp)
versus the logarithm of the number of copies. Standard
dilutions were optimized to cover the relevant concentra-
tion range of target and reference RNA in the sample. In
every run, water was included as a negative control to
check for cross contamination. The specific primer
sequences used for real-time PCR were the following: for
uPA [GenBank: NM_002658]: sense, 5'-CAGGGCATCTC-
CTGTGCATG-3'(position 1661–1680), antisense,
5'AGCCCTGCCCTGAAGTCGTTA-3' (position 1834–
1855); for PAI-1  [GenBank: NM_000602]: sense, 5'-
GGGCCATGGAACAAGGATGA-3' (position 394–413),
antisense, 5'-CTCCTTTCCCAAGCAAGTTG-3' (position
591–610); for PPIB [GenBank: NM_000942]: sense, 5'-
AGGAGAGAAAGGATTTGGCT-3' (position 231–250),
antisense 5'-CAGGCTGTCTTGACTGTCGTGA-3' (posi-
tion 449–470).
Statistical analysis
UPA and PAI-1 mRNA values were compared with clini-
cal, histological and biological features of tumors using
appropriate statistical tests. Differences were considered
to be statistically significant when p was < 0.05. Metasta-
sis-free Survival (MFS) time (defined as the time from sur-
gery until detection of a distant metastasis) and Breast
Cancer specific Survival (BCS) time (defined as the time
between the date of surgery and death provoked by can-
cer) were used as follow-up endpoints. The "distant
metastasis" definition did not take into account second
cancer or loco-regional relapse and only distant metastasis
was considered as an event. Furthermore, MFS does not
include deaths without a prior cancer event. For the uni-
variate and multivariate analyses, we investigated the
prognostic value of uPA and PAI-1 mRNA levels by using
the median of expression generating "high" and "low"
level groups. For each parameter, MFS and BCS were cal-
culated according to the method of Kaplan and Meier [17]
and compared using the log-rank test [18]. The results of
the multivariate analysis were expressed in terms of haz-
ard ratio derived from the estimated regression coeffi-
cients, along with their 95% confidence intervals (CI).
Table 1: Clinical characteristics of the patients
Characteristics Total (n = 87)
Age at Diagnosis (years)
Median (range) 54 (29–74)
Average (SEM) 53 (1.0)
Age categories
< 50 years 30 (35%)
≥ 50 years 57 (65%)
Primary surgery
Mastectomy 48 (55%)
Lumpectomy 39 (45%)
Histological type
Ductal 79 (90%)
Lobular 5 (6%)
Other 3 (4%)
Histological grade
SBR I 12 (14%)
SBR II 47 (54%)
SBR III 28 (32%)
Tumor size
T1 11 (13%)
T2 63 (72%)
T3 13 (15%)
Nb. positive nodes
1–3 55 (63%)
≥ 4 32 (37%)
ER status (IHC)
positive 83 (96%)
negative 4 (4%)
PR status (IHC)
positive 80 (92%)
negative 7 (8%)
Cancer-provoked death
Yes 22 (26%)
No 65 (74%)
Metastasis-relapse
Yes 30 (35%)
No 57 (65%)
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; 
IHC, immunohistochemistry; SBR, Scarff Bloom and Richardson.BMC Cancer 2006, 6:216 http://www.biomedcentral.com/1471-2407/6/216
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Multivariate analyses based on the Cox proportional haz-
ards model [19] were used to identify the most significant
factors related to MFS and BCS.
Results
RT-PCR analysis of uPA and PAI-1 gene expression
Real-time quantitative RT-PCR was carried out to measure
uPA and PAI-1 mRNA expression between relapsed and
non-relapsed breast cancers on the 87 samples studied
using the cyclophilin B (PPIB) gene, known to be stably
expressed in breast tissues, as an internal control [20]. As
shown in Figure 1, significant differential PAI-1  gene
expression was observed between relapsed and non-
relapsed breast cancers (Mann-Whitney p < 0.0001). Sim-
ilarly, the difference of expression was statistically signifi-
cant between survivors and patients that died of breast
cancer (Figure 2; Mann-Whitney p < 0.0001). In contrast,
uPA  expression levels were not significantly different
between breast cancers (data not shown; Mann-Whitney p
= 0.09 and p = 0.11 for MFS and BCS, respectively).
Correlation between uPA and PAI-1 mRNA values with 
patient characteristics
The relationship between uPA/PAI-1  mRNA levels and
patient and tumor characteristics is shown in Table 2.
There was no statistically significant correlation between
uPA mRNA content and age, tumor size, lymph nodes sta-
tus, age categories, histological types or histological grade.
Similarly, the PAI-1 expression level was not found to be
correlated with any of the established clinical and patho-
logical factors.
Univariate and multivariate analysis of uPA and PAI-1 
mRNA values for MFS
Univariate and multivariate analysis of metastasis-free
survival was performed for all parameters. In univariate
analysis, we observed that tumor size (p = 0.0002), and
the number of lymph nodes involved (p = 0.002) are of
prognostic value for MFS (Table 3). Interestingly, uPA and
PAI-1 mRNA expression may also be considered as signif-
icant prognostic factors with strong p-values (p = 0.0005
and p < 0.0001 respectively). Kaplan-Meier survival curves
representing the probability of metastasis-free survival as
a function of PAI-1 and uPA status are represented in Fig-
ures 3 and 4 respectively. We investigated the prognostic
value of uPA and PAI-1 mRNA levels by considering the
median of expression as a cut-off generating a "high" and
a "low" level group. The medians used corresponded to a
PAI-1/PPIB and a uPA/PPIB expression ratio of 0.25 and
2.12 respectively. As shown in Figure 3, MFS was signifi-
cantly shorter in patients expressing high level of PAI-1
mRNA (p < 0.0001). In contrast, low uPA mRNA expres-
sion was not significantly associated with longer metasta-
sis-free survival (p = 0.41) (Figure 4).
The independent relationship of uPA and PAI-1 gene
expression with MFS was also studied using Cox-multivar-
iate regression analysis. We could thereby establish
whether the prognostic value of each marker as found in
PAI-1 mRNA expression in relapsed and non-relapsed breast  cancer patients as measured by quantitative RT-PCR Figure 2
PAI-1 mRNA expression in relapsed and non-relapsed breast 
cancer patients as measured by quantitative RT-PCR. Differ-
ential PAI-1 gene expression between survivors (n = 65) and 
non-survivors (n = 22) with BCS as end-point (Mann-Whit-
ney test; p < 0.0001).
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PAI-1 mRNA expression in relapsed and non-relapsed breast  cancer patients as measured by quantitative RT-PCR Figure 1
PAI-1 mRNA expression in relapsed and non-relapsed breast 
cancer patients as measured by quantitative RT-PCR. Differ-
ential PAI-1 gene expression between relapsed (n = 30) and 
non-relapsed (n = 57) patients with MFS as end-point (Mann-
Whitney test; p < 0.0001).
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the univariate analysis was attributed to its relationship
with other clinicopathological factors or whether these
factors themselves contribute independently to prognosis.
As shown in Table 3, tumor size, age categories and PAI-1
mRNA expression are of prognostic value for MFS while
lymph node status, histological type, histological grade
and uPA expression did not add significant independent
prognostic information. The tumor size is positively cor-
related to metastasis-relapse since the risk of relapse is
higher for larger tumors than for smaller tumors (p =
0.01). Moreover, the risk of relapse for patients older than
50 years is 3.38 times that found in younger women (p =
0.04). Finally, high levels of PAI-1 mRNA appeared to be
the strongest prognostic factor with a relative risk of 10.12
(p = 0.0002).
Univariate and multivariate analysis of uPA and PAI-1 
mRNA values for BCS
Univariate and multivariate analysis were performed
using all of the prognostic factors with breast cancer spe-
cific survival as the follow-up end point. In univariate
analysis, tumor size (p = 0.01), number of lymph nodes
involved (p = 0.004), high uPA levels (p = 0.02) and high
PAI-1 levels (p < 0.0001) are of prognostic value for BCS
(Table 4). As for PAI-1, Kaplan-Meier survival curves rep-
resenting probability of breast cancer survival as a func-
tion of PAI-1 and uPA status are represented in Figures 5
and 6 respectively. We observed that the probability of
BCS was significantly lower in patients expressing a high
level of PAI-1 mRNA (p < 0.0001; Figure 5) while no sig-
nificant difference in BCS was observed between patients
expressing low and high uPA levels (p = 0.19; Figure 6).
In a Cox-multivariate regression analysis, only tumor size
(p = 0.05), age categories (p = 0.04), and PAI-1 mRNA
expression (p = 0.0003) are of prognostic value for BCS
while number of lymph nodes, histological type, histolog-
ical grade and uPA expression did not add any significant
independent prognostic value (Table 4).
Discussion
The plasminogen activation system plays a role in cancer
progression via extracellular matrix degradation and
tumor cell migration [21]. Numerous research groups
have demonstrated that the antigen content of uPA and
PAI-1 in primary breast cancer tissue correlates with dis-
ease aggressiveness and has a strong prognostic impact on
primary breast cancer [1-6,21,22]. All these data have
Table 2: Association of clinico-pathological factors with uPA and 
PAI-1 mRNA expression.
Variable uPA PAI-1
p-value p-value
Age * 0.29 0.3
Tumor size * 0.93 0.95
Lymph nodes * 0.4 0.2
Age categories ** 0.2 0.65
< 50 years
≥ 50 years
Histological Type ** 0.97 1.0
Ductal
Other
Histological grade *** 0.76 0.89
SBRI
SBRII
SBRIII
* Spearman rank correlation test
** Wilcoxon rank test
*** One-way ANOVA
Abbreviations: SBR, Scarff Bloom and Richardson.
Table 3: Univariate and multivariate analyses for Metastasis-Free Survival
Variable Univariate Multivariate
p-value Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI)
Tumor size 0.0002 1.03 (1.01–1.05)
T3 vs T1, T2 0.01 9.3 (1.49–58.04)
Lymph nodes 0.002 1.07 (1.02–1.13)
≥ 3 vs < 3 0.75 1.19 (0.39–3.56)
Age categories 0.08 2.08 (0.89–4.88)
≥ 50 years vs < 50 years 0.04 3.38 (1.05–10.87)
Histological Type 0.2 3.37 (0.45–24.83)
Ductal vs others 0.23 4.08 (0.39–42.23)
Histological grade 0.88 1.14 (0.65–2.01)
SBRII vs I 0.65 1.46 (0.27–7.7)
SBRIII vs I 0.6 1.6 (0.27–9.5)
uPA High vs Low 0.0005 1.14 (1.05–1.24) 0.62 1.31 (0.44–3.93)
PAI-1 High vs Low <0.0001 5.56 (2.32–13.28) 0,0002 10.12 (3.03–33.76)
Abbreviations: SBR, Scarff Bloom and Richardson.BMC Cancer 2006, 6:216 http://www.biomedcentral.com/1471-2407/6/216
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been obtained at the protein level using quantitative
enzyme-linked immunosorbent assay (ELISA)-based
methods applied to cytosol. The EORTC Receptor and
Biomarker Study Group initiated quality control pro-
grams for this type of assay [23]. However, the use of this
method encounters major limitations in routine clinical
practice. Although being robust, reproducible and qual-
ity-assured, the ELISA requires a substantial amount of
frozen tissue, which compromises its use in small tumors
(< 1 cm) and requires adequate logistics for the storage of
frozen tumor samples. Furthermore, the biochemical
methods have been abandoned to the detriment of immu-
nohistochemical methods for hormone receptor assess-
ment in an increasing number of pathology laboratories.
Unfortunately, immunohistochemical assays of the uPA/
PAI-1 system have provided unsatisfactory results mainly
due to an absence of consensus regarding uPA and PAI-1
cellular localization [24]. The measurement of uPA- and
PAI-1-expression at the mRNA level using molecular biol-
ogy techniques could thus constitute an alternative to the
immunochemical assays currently being used. Indeed,
real-time quantitative NASBA or RT-PCR needs very low
quantities of material (< 100 ng of total RNA) and thus
allows for the analysis of smaller tumors. Moreover, the
availability of aqueous tissue storage reagents that rapidly
permeate tissue to stabilize and protect cellular RNA in
unfrozen specimens will facilitate routine laboratory use
of those techniques.
Previous studies focused on messengers of the compo-
nents of the plasminogen activation system in human
breast cancer by mainly comparing normal, benign and
malignant breast tissues or by examining the cellular
localization of uPA and PAI-1 [25-30]. More recently, Cas-
tello et al. [31] developed a quantitative real-time RT-PCR
assay and showed that uPA and PAI-1 mRNA expression
increased with tumor severity in breast cancer, thereby
confirming previous results obtained by Northern blot-
ting [32]. Moreover, it has been demonstrated that high
uPA and PAI-1 mRNA expression was significantly associ-
ated with shorter disease-free survival in a population of
130 primary breast cancers independent of the hormone
receptor and the lymph node status [33].
To our knowledge, we are the first to evaluate the prognos-
tic impact of uPA and PAI-1 at the mRNA level in a specific
group of lymph node positive- and hormone receptor-
positive breast cancers. In the present study, we show that
PAI-1 mRNA, as measured by quantitative RT-PCR in the
primary tumors, has the strongest prognostic value for
MFS and BCS. We also observed that the prognostic value
of PAI-1 is stronger that of uPA. Increased uPA messenger
level was also associated with metastasis-free survival and
breast cancer specific survival in univariate analysis, but
did not represent a statistically significant independent
prognostic factor. The fact that histological grade, one of
the most important prognostic factors in hormone recep-
tor-positive breast cancer did not emerge as an independ-
ent factor in our analysis was not expected. A major reason
might be that we selected a specific population of hor-
mone receptor- and node-positive breast cancer with
mainly large tumors. This selection bias might, besides the
quite small number of patients, explain these results.
Our results are in accordance with previous studies show-
ing that PAI-1 protein displayed stronger prognostic
impact than uPA in lymph node-positive patients and that
this marker remained a strong prognostic factor after long-
Metastasis-free Survival of patients according to uPA gene  expression Figure 4
Metastasis-free Survival of patients according to uPA gene 
expression. The high uPA expression group (n = 44; 17 
events) did not show significantly poorer MFS rates than the 
low uPA expression group (n = 43; 13 events; p = 0.41, log-
rank test).
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Metastasis-free Survival of patients according to PAI-1 gene  expression Figure 3
Metastasis-free Survival of patients according to PAI-1 gene 
expression. The high PAI-1 expression group (n = 43; 23 
events) showed significantly poorer MFS rates than the low 
PAI-1 expression group (n = 44; 7 events; p < 0.0001, log-
rank test).
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term follow-up both for primary breast cancer and after
the first relapse [4,34]. Moreover, it has recently been
shown that PAI-1 mRNA expression increased with color-
ectal cancer and the oesophageal squamous carcinoma
stage and was associated with poor prognosis suggesting
that the gene expression of this marker may serve as a new
prognostic factor in these two types of cancer [35,36].
Conclusion
Taken together, these results demonstrate that a high PAI-
1 gene expression level represents a strong and independ-
ent unfavorable prognostic factor for the development of
metastases and for overall survival in a population of
lymph node- and receptor-positive breast cancer. In this
specific group of patients, the measurement of the PAI-1
mRNA level, in addition to the clinicopathological
parameters usually considered, may help clinicians to pro-
pose a more aggressive chemotherapy (e.g. taxanes
instead of anthracyclines) in addition to the endocrine
therapy in bad prognosis patients. Moreover, assessing the
PAI-1 mRNA level may also be useful to stratify candidates
for the anti-PAI-1 targeted therapies currently being eval-
uated [37]. These findings also suggest that for this
marker, molecular biology-based techniques such as real-
time quantitative NASBA or RT-PCR may be envisaged in
the future as an alternative to the ELISA method currently
used.
Breast Cancer specific Survival of patients according to uPA  gene expression Figure 6
Breast Cancer specific Survival of patients according to uPA 
gene expression. The high uPA expression group (n = 44; 15 
events) did not show significantly poorer BCS rates than the 
low uPA expression group (n = 43; 8 events; p = 0.19, log-
rank test).
0 25 50 75 100 125 150 175
0.00
0.25
0.50
0.75
1.00
uPA High
(n=44; 15 events)
uPA Low
(n=43; 8 events)
p = 0.19
Months
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
B
C
S
Table 4: Univariate and multivariate analyses for Breast Cancer specific Survival
Variable Univariate Multivariate
p-value Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI)
Tumor size 0.01 1.02 (1–1.05)
T3 vs T1, T2 0.05 6.5 (0.99–42.58)
Lymph nodes 0.004 1.08 (1.02–1.15)
≥ 3 vs < 3 0.77 1.19 (0.35–4.02)
Age categories 0.29 1.64 (0.64–4.18)
≥ 50 years vs < 50 years 0.04 3.63 (1.04–12.6)
Histological Type 0.14 1.05 (0.72–1.25)
Ductal vs others 0.96 1.65 (0.3–4.56)
Histological grade 0.85 1.04 (0.53–2.03)
SBRII vs I 0.68 0.69 (0.12–3.97)
SBRIII vs I 0.57 0.57 (0.08–3.83)
uPA High vs Low 0.02 1.11 (1.01–1.23) 0.13 2.57 (0.74–8.9)
PAI-1 High vs Low <0.0001 7.61 (2.55–22.71) 0.0003 13.17 (3.26–53.17)
Abbreviations: SBR, Scarff Bloom and Richardson.
Breast Cancer specific Survival of patients according to PAI-1  gene expression Figure 5
Breast Cancer specific Survival of patients according to PAI-1 
gene expression. The high PAI-1 expression group (n = 43; 19 
events) showed significantly poorer BCS rates than the low 
PAI-1 expression group (n = 44; 4 events; p < 0.0001, log-
rank test).
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